This histogram enumerates side effects from a completed 2020 Phase 2 trial (NCT03736785) in the LY3209590 Algorithm 2 ARM group. Side effects include: Upper respiratory tract infection with 11%, Diarrhoea with 6%, Dizziness with 5%, Cough with 4%, Hypoglycaemia with 2%.
2 Treatment Groups
1 of 2
1 of 2
670 Total Participants · 2 Treatment Groups
Primary Treatment: LY3209590 · No Placebo Group · Phase 3
Experimental Group · 1 Intervention: LY3209590 · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Insulin Degludec · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2
Screening: ~3 weeks
Reporting: week 22 to week 26
Closest Location: Dallas Diabetes Research Center · Dallas, TX
2021First Recorded Clinical Trial
17 TrialsResearching Diabetes Mellitus
11 CompletedClinical Trials
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a clinical diagnosis of type 1 diabetes for at least 1 year prior to screening.
You have a body mass index of ≤35 kg/m².
You have received treatment with basal-bolus insulin analog multiple daily injection therapy according to the local product label for at least 90 days prior to screening.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.